Krzysztof Pyrć

Professor; Laboratory of Virology of the Malopolska Centre of Biotechnology, Jagiellonian University, Cracow, Poland


Virologist. Graduated from Jagiellonian University (M.Sc.), University of Amsterdam (Ph.D.), and University of Lodz (habilitation).


In January 2019 received the title of Professor in the field of biological sciences. He specializes in emerging RNA viruses (mainly coronaviruses and flaviviruses), with particular emphasis on mechanisms of infection and the development of new therapeutic strategies. Head of the Laboratory of Virology at the Malopolska Centre of Biotechnology, Jagiellonian University. A certified project manager. Leader of Virogenetics research group, supervisor, and promoter of students and Ph.D. students. Authored over 100 publications in journals as Nature Medicine, Science Translational Medicine, PNAS, PLoS Pathogens, Journal of Virology, and Science Signaling, which have been cited nearly four thousand times in the world literature. Reviewer and expert in science funding institutions in Poland and abroad (Horizon2020, ERC, FNP, NCN, and others).


Author of several patent applications and patents, on the basis of which 2 spin-off companies have already been established (Acatavir and StartIt Vet). Manager and coordinator of numerous research grants, including under Horizon2020, IMI2, European Cooperation in Science and Technology, NCN, FNP, NCBIR, and MNiSW, as well as grants funded by commercial entities. Member of the advisory team of the Minister of Science and Higher Education for activities related to the prevention, counteraction, and eradication of COVID-19.  Deputy chairman of the advisory team (COVID-19) to the President of the Polish Academy of Sciences, member of the scientific board of the initiative Science against Pandemic. Member of the Medical Council to the Prime Minister. Member of the Healthcare Council to the President of the Republic of Poland. Expert of the Agency for Health Technology Assessment and Tarification – AOTMiT in the field of SARS-CoV-2 therapy and diagnostics.


Congratulation letter from ACCORD and Faculty of Pharmacy